Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months - United States, April 2024

• 2024

  Log in to bookmark this resource.

  Log in
• Hilda Razzaghi; Emma Garacci; Katherine Kahn; Megan Lindley; Jefferson Jones; Shannon Stokley
PMID: 39325675DOI: https://dx.doi.org/10.15585/mmwr.mm7338a2

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This article is about a study on RSV vaccination for pregnant women and their babies in the U.S. It describes how RSV is a common cause of hospital visits for infants. The study found that 33% of pregnant women got the vaccine, and 45% of babies received an antibody called nirsevimab. Overall, 56% of infants were protected from severe RSV disease by either or both methods. It highlights that doctors' recommendations increased vaccination rates and suggests more efforts are needed to improve these numbers to protect infants better from RSV-related illnesses.

---

Tags

Focus Area: Infectious Disease

Audiences: Nurses; Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Immunization; Infant; Maternal Health Services; Pregnant Women; Respiratory Syncytial Viruses; United States; Immunization Programs; Respiratory Syncytial Virus Vaccines; Antibodies, Monoclonal, Humanized; Vaccination Coverage

Institutions: Centers for Disease Control and Prevention (CDC)

---

More like this

Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024 2024 · Centers for Disease Control and Prevention (CDC), Maximus Federal Services, Inc., ICF Meeting Summary: State and Local Implementation Strategies for Increasing Access to Contraception During Zika Preparedness and Response — United States, September 2016 2017 · Centers for Disease Control and Prevention (CDC), Association of Schools & Programs of Public Health Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children 2024 · University of Michigan, Centers for Disease Control and Prevention (CDC), U.S. Public Health Service

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---